AstraZeneca Pharma India Limited has informed the Exchange regarding 'Determination of materiality details of Key Managerial Personnel'.
ASTRAZEN · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
AstraZeneca Pharma India has filed a routine compliance disclosure with BSE and NSE listing the contact details of its Key Managerial Personnel (KMPs) who are authorized to determine whether an event or piece of information is 'material' enough to be reported to the stock exchanges. The filing is made under Regulation 30(5) of SEBI's Listing Obligations and Disclosure Requirements Regulations, 2015. Three KMPs are authorized, either jointly or individually: Managing Director Praveen Rao Akkinepally, Chief Financial Officer and Director Bhavana Agrawal, and Company Secretary Manasa. R. This is a procedural disclosure and not a new appointment or change in leadership.
No impact on shareholders or stock price. This is a standard regulatory filing required by SEBI and does not signal any change in management, strategy, or business performance.